Blood & Cancer Center of East Texas

Tyler, Texas 75701

0 studies enrolling now · 2 studies all time

What they study most

Multiple Myeloma

Studies at this site

• Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib — Stopped early
• Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients — Completed